MarketBeat
18 Aug 2026, 04:02 UTC · 1h ago
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
18 Aug 2026, 04:02 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
TriSalus expects to become cash-flow positive upon reaching an annualized revenue run rate of approximately $80 million. — Provides a concrete financial milestone for profitability, which is a primary valuation driver for small-cap life sciences companies.
+0.60The company is awaiting FDA clearance for TriNav ADVANCE, a product that could address 20% of the 'super selective' procedure market. — Regulatory approval for a product expanding the total addressable market (TAM) serves as a significant near-term catalyst.
+0.50TriSalus estimates a potential gross margin of approximately 93% for its product offerings. — Extremely high margins suggest strong scalability and the ability to absorb commercial expansion costs.
+0.40Continue reading
6 related stories
Search tags
A new permanent CMS G-code for reimbursement is expected to become effective on January 1, potentially expanding access in the office-based lab market. — Improved reimbursement typically lowers barriers to physician adoption and accelerates revenue growth.
+0.30The company expanded its commercial organization in H1, with new representatives currently in a six-to-nine-month ramp-up period. — While necessary for growth, the lag in representative productivity creates a short-term delay in revenue acceleration.
+0.10Which stocks this story touches
The company reported strong product efficacy, expanded its sales force, and highlighted high potential gross margins and a growing addressable market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
23h ago
